title: Cannabinoid receptor-2 and HIV-associated neurocognitive disorders.
abstract: Despite the wide spread use of highly active antiretroviral therapy (HAART), mild forms of HIV-associated neuro cognitive disorders (HAND) remain commonplace. HAART treated patients now show low levels of viremia and more subtle yet biologically important signs of brain macrophage and microglial activation. Adjunctive therapeutic strategies are required to eliminate HIV-1 infection and suppress immune activation and its associated neuroinflammation. In this regard, cannabinoid receptor-2(CB2) activation is a promising means to attenuate HAND by inhibiting HIV replication, down regulating inflammation, and suppressing chemokine-like activity of viral neurotoxic proteins (for example, Tat and HIV-1gp120), and thereby prevent neuronal and synaptic loss. Inhibiting even low level HIV replication can attenuate neuronal injury by decreasing the production of neurotoxins. Down regulation of inflammation by CB2 activation is mediated through blunted activation of peri vascular macrophages and microglia; decreased production of tumor necrosis factor-α, chemokines and virotoxins. Down regulated neuroinflammation can decrease blood brain barrier permeability and leukocyte infiltration resulting in reduced neuronal injury. It is suggested that CB2 agonists may further attenuate HAND in HIVinfected patients on HAART. In addition, CB2 activation may also blunt brain injury by attenuating drug addiction.
authors.forename: Vishnudutt
authors.initials: V
authors.lastname: Purohit
authors.forename: Rao S
authors.initials: RS
authors.lastname: Rapaka
authors.forename: Joni
authors.initials: J
authors.lastname: Rutter
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D002186:Cannabinoids / Q000494:pharmacology; D018925:Chemokines / Q000378:metabolism; D019970:Cocaine-Related Disorders / Q000150:complications / Q000503:physiopathology; D003072:Cognition Disorders / Q000150:complications / Q000473:pathology* / Q000523:psychology / Q000821:virology*; D049229:Dendritic Spines / Q000473:pathology; D015536:Down-Regulation; D015696:Gene Products, tat / Q000378:metabolism; D006678:HIV / Q000502:physiology; D015658:HIV Infections / Q000150:complications / Q000378:metabolism* / Q000523:psychology* / Q000821:virology; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000503:physiopathology; D008262:Macrophage Activation; D009410:Nerve Degeneration / Q000150:complications / Q000473:pathology; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014764:Viral Proteins / Q000037:antagonists & inhibitors; D014779:Virus Replication / Q000502:physiology
chemical_list: D002186:Cannabinoids; D018925:Chemokines; D015696:Gene Products, tat; D043885:Receptor, Cannabinoid, CB2; D014409:Tumor Necrosis Factor-alpha; D014764:Viral Proteins